Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05CHR
|
|||
| Former ID |
DIB014947
|
|||
| Drug Name |
LBY-135
|
|||
| Synonyms |
LCR-211; Anti-DR5 agonist chimerics mAb (cancer), Novartis; Anti-death receptor5 agonist chimeric monoclonal antibody (cancer), Novartis
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Discontinued in Phase 1 | [1] | |
| Company |
Novartis AG
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026275) | |||
| REF 2 | Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs. 2014 Feb;32(1):135-44. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.